Supplemental Digital Content 2. Reverse cumulative curves for rSBA-MenC antibody titer 66 months after the booster dose (ATP cohort for persistence at month 66)

Hib-MenC-TT primed/Hib-MenC-TT booster group received Hib-MenC-TT + DTPa-HBV-IPV at 2-4-6 months and Hib-MenC-TT booster dose at 13–14 months of age.

MenC-TT primed/Hib-MenC-TT booster group received MenC-TT at 2-4 months + DTPa/Hib containing vaccines at 2-4-6 months and Hib-MenC-TT booster dose at 13–14 months of age.

MenC-CRM control group received MenC-CRM$_{197}$ + DTPa-HBV-IPV/Hib at 2-4-6 months and DTPa-HBV-IPV/Hib booster dose at 13–14 months of age. An additional dose of MenC-CRM$_{197}$ was received 1 month after the DTPa-HBV-IPV/Hib booster dose.